Chemical Abortion Crisis Hits Congress

Senator Josh Hawley just introduced a bold bill to yank FDA approval from the dangerous chemical abortion drug mifepristone, protecting women from its hidden risks after years of government negligence.

Story Highlights

Hawley unveils Safeguarding Women from Chemical Abortion Act to revoke FDA approval of mifepristone and allow harmed women to sue manufacturers like Danco Laboratories.
Press conference on March 11, 2026, features testimonies from women injured by the drug and pro-life leaders demanding action.
Complications from mifepristone are 22 times higher than FDA labels claim, per EPPC research, exposing corporate profiteering.
Companion bill planned in House by Rep. Diana Harshbarger amid Trump administration’s ongoing FDA review delays.
Builds on Biden-era expansions of mail-order abortions, now challenged in Republican-led Congress.

Bill Targets FDA Overreach on Mifepristone

U.S. Senator Josh Hawley (R-Mo.) introduced the Safeguarding Women from Chemical Abortion Act on March 11, 2026. The legislation withdraws FDA approval of mifepristone for abortion use. It classifies distribution for pregnancy termination as a violation of the Federal Food, Drug, and Cosmetic Act. Women harmed by complications gain a private right of action to sue manufacturers. Danco Laboratories faces direct accountability for billions in profits from the drug. This targets risks hidden by lax regulations.

Press Conference Spotlights Real Harm to Women

Hawley hosted a press conference on March 11, 2026, unveiling the bill with powerful testimonies. Women shared stories of severe injuries from mifepristone, the first drug in chemical abortion regimens. Pro-life leaders joined, urging Congress to override FDA inaction. Concerned Women for America Legislative Action Committee commended the effort as a necessary step against the dangerous drug. These accounts highlight unregulated mail-order access fueling abuse and health crises. Families deserve protection from such corporate greed.

Historical FDA Failures and Biden Expansions

The FDA approved mifepristone in 2000 under President Clinton for early pregnancy termination. Biden-era rules eased in-person requirements, enabling telehealth and mail-order prescriptions. The 2024 Supreme Court ruling upheld access by dismissing a challenge on standing grounds, not merits. Medication abortions comprised 63% of U.S. cases in 2023, rising to over 1 million clinician-provided in 2024 per Guttmacher data. Trump administration retained these rules despite pro-life pressure, opting for a year-long FDA review and approving generics. Hawley’s prior May 2025 bill sought safeguards; this version goes further by revoking approval outright.

EPPC Data Reveals Alarming Safety Gaps

Ethics and Public Policy Center research shows mifepristone complications occur 22 times more frequently than FDA labels indicate. Hawley cited this science, declaring the drug inherently dangerous and prone to abuse. Pro-life groups like Restoration of America Foundation note mail-order drives 500 daily chemical abortions, pressuring Trump for reversal. FDA Commissioner Marty Makary pledged data review after Hawley’s urging, but timelines remain unclear. Opponents emphasize unregulated risks over proponents’ safety stats. Congress must act where agencies falter to safeguard women’s health and traditional values.

.@HawleyMO: Congress MUST BAN the chemical abortion drug.https://t.co/niaM5omc01 pic.twitter.com/GCfCn8LWPX

— LifeSiteNews (@LifeSite) March 12, 2026

Political Path Forward Faces Hurdles

The bill entered the Senate with a House companion from Rep. Diana Harshbarger (R-TN-01). No committee action reported yet in Republican-controlled Congress. Trump pledged to veto national abortion bans in 2024, signaling low passage odds. State lawsuits paused by Trump DOJ for FDA review. Long-term, passage could ban most medication abortions, shifting to surgical options and enabling manufacturer lawsuits. It tests GOP unity amid 2026 midterms, hitting Danco’s revenue while altering post-Dobbs landscape. Pro-life advocates see victory for family values; access groups warn of restrictions.